Study of the depressive disorders in patients with myasthenia gravis

Authors

  • Oleksandr Kalbus SE “ Dnipropetrovsk Medical Academy of the Ministry of Health of Ukraine” Volodymyra Vernadskoho str., 9, Dnipro, Ukraine, 49044, Ukraine https://orcid.org/0000-0003-0796-4825

DOI:

https://doi.org/10.15587/2519-4798.2018.121973

Keywords:

myasthenia, depression, antibodies, acetylcholine receptors, muscle-specific tyrosine-kinase, ophthalmic form, generalized form

Abstract

Aim of the research: To study depressive manifestations in patients with myasthenia depending on the duration, clinical form and immunological type of the disease.

Methods: A neurological examination, determination of antibodies to acetylcholine receptors and muscle-specific tyrosine-kinase, a Beck depression score of 96 patients with myasthenia was performed.

Results: The average age of patients was 50.5±12.4 years, the average duration of the disease was 4.4±1.2 years. Antibodies to acetylcholine receptors were detected in 57 (80.3 %) of 71 patients with generalized form and in 13 (52 %) of 25 patients with ophthalmic myasthenia. In 6 (8.5 %) of 71 patients with generalized myasthenia, antibodies to muscle-specific tyrosine-kinase were detected. In 8 (11.3 %) out of 71 patients with a generalized form of myasthenia and 12 (48.0 %) out of 25 patients with an ocular form of myasthenia antibodies were not detected. Depressive manifestations in the form of mild (32 persons) and moderate (34 persons) depression were detected in 66 patients, the mean score on the Beck scale was 12.9±3.45 points). In patients with a generalized form of myasthenia, the incidence of mild to moderate depression does not significantly differ, with no significant difference in the average duration of the disease in these groups of patients. At the same time, in patients with generalized myasthenia without manifestations of depression, the average duration of the disease was significantly lower. The presence and degree of manifestations of depressive disorders does not depend on the presence of antibodies to the receptors of acetylcholine, antibodies to muscle-specific tyrosine-kinase or their absence.

Conclusions: As a result of the work, it was found that the development of depressive disorders in patients with myasthenia increases with the duration of the disease. Depressive manifestations are more pronounced in patients with generalized myasthenia in compare to patients with ophthalmic form.

The development and degree of depressive manifestations does not depend on the immune type of myasthenia

Author Biography

Oleksandr Kalbus, SE “ Dnipropetrovsk Medical Academy of the Ministry of Health of Ukraine” Volodymyra Vernadskoho str., 9, Dnipro, Ukraine, 49044

PhD, Assistant

Department of Neurology and Ophthalmology

References

  1. Kulikova, S. L. (2014). Antitela k atsetilholinovyim retseptoram v diagnostike razlichnyih form miastenii. Nevrologiya i neyrohirurgiya Vostochnaya Evropa, 1 (21), 73–82.
  2. Skeie, G. O., Apostolski, S., Evoli, A., Gilhus, N. E., Illa, I., Harms, L. et. al. (2010). Guidelines for treatment of autoimmune neuromuscular transmission disorders. European Journal of Neurology, 17 (7), 893–902. doi: 10.1111/j.1468-1331.2010.03019.x
  3. Shkolnik, V. M., Kalbus, A. I., Baranenko, A. N., Pogorelov, A. V. (2014). Miasteniya: sovremennyie podhodyi k diagnostike i lecheniyu. Ukrainskyi nevrolohichnyi zhurnal, 2, 12–17.
  4. Shkolnik, V. M., Kalbus, A. I., Shulga, O. D. (2010). Miasteniya: chto nam izvestno segodnya? Zdorov’ya Ukrayiny (nevrologiya, psyhiatriya, psyhoterapiiya), 3 (14), 10–11.
  5. Shulga, O. D., Kalbus, A. I., Shulga, L. A. (2010). Miasteniya. Neyron Revyu, 2, 13–20.
  6. Kulaksizoglu, I. B. (2007). Mood and Anxiety Disorders in Patients with Myasthenia Gravis. CNS Drugs, 21 (6), 473–481. doi: 10.2165/00023210-200721060-00004
  7. Aysal, F., Karamustafalioglu, O., Ozcelik, B., Yilmaz, M., Karamustafalioglu, N., Yumrukcal, H., Tankaya, O. (2013). The relationship of symptoms of anxiety and depression with disease severity and treatment modality in myasthenia gravis: a cross-sectional study. Archives of Neuropsychiatry, 50 (4), 295–300. doi: 10.4274/npa.y5611
  8. Gulec Uyaroglu, F., Bilgin, S., Keles, E. H., Zorlu, Y. (2016). Anxiety And Depression Symptoms In Patients With Generalized Myasthenia Gravis. The Journal of Tepecik Education and Research Hospital, 26 (2), 97–103 doi: 10.5222/terh.2016.097
  9. Suzuki, Y., Utsugisawa, K., Suzuki, S., Nagane, Y., Masuda, M., Kabasawa, C. et. al. (2011). Factors associated with depressive state in patients with myasthenia gravis: a multicentre cross-sectional study. BMJ Open, 1 (2), 1–7. doi: 10.1136/bmjopen-2011-000313
  10. Blum, S., Lee, D., Gillis, D., McEniery, D. F., Reddel, S., McCombe, P. (2015). Clinical features and impact of myasthenia gravis disease in Australian patients. Journal of Clinical Neuroscience, 22 (7), 1164–1169. doi: 10.1016/j.jocn.2015.01.022

Published

2018-01-29

How to Cite

Kalbus, O. (2018). Study of the depressive disorders in patients with myasthenia gravis. ScienceRise: Medical Science, (1 (21), 32–34. https://doi.org/10.15587/2519-4798.2018.121973

Issue

Section

Medical Science